Using the same dosing and sampling regimen, our group has also reported that colchicine reduces the transcoronary concentration of MCP-1, chemokine ligand 5 and fractalkine [73], all of which have been previously implicated in the pathogenesis of atherosclerosis and atherothrombosis. The gene discussed is CCL2; the disease is atherosclerosis.